3-Drug Combination ‘Extremely Promising’ As First-Line Therapy For Multiple Myeloma
A new combination of bortezomib (Velcade) and two other drugs is showing a very high response rate in patients newly diagnosed with multiple myeloma, a team headed by Dana-Farber Cancer Institute investigators reported at the annual meeting of the American Society of Hematology. [click link for full article]
More: continued here
Filed under: Blood on December 15th, 2007